anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (Wayne State University/Barbara Ann Karmanos Cancer Institute)

N/A

Report date: 2026/03/19 16:58:30

Base Information

Drug Nameanti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (Wayne State University/Barbara Ann Karmanos Cancer Institute)
Drug Alias NameCD20Bi aATCCD20Bi activated T-cells (Wayne State University/Barbara Ann Karmanos Cancer Institute)CD20Bi-armed ATC (Wayne State University/Barbara Ann Karmanos Cancer Institute)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBarbara Ann Karmanos Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWayne State UniversityBarbara Ann Karmanos Cancer Institute
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A